Published in Asia Pac J Clin Oncol on December 01, 2010
Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res (2013) 1.95
Pemetrexed for malignant pleural mesothelioma: Is it a standard second-line therapy? Asia Pac J Clin Oncol (2010) 0.75
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol (2003) 5.84
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Mesothelin-family proteins and diagnosis of mesothelioma. Lancet (2003) 2.98
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer (2010) 2.73
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer (2006) 1.75
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res (2013) 1.55
Squamoproliferative lesions arising in the setting of BRAF inhibition. Am J Dermatopathol (2012) 1.51
Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res (2009) 1.32
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis (2013) 1.27
Measurement of lung tumor volumes using three-dimensional computer planning software. Int J Radiat Oncol Biol Phys (2002) 1.25
Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. Chest (2012) 1.18
Diagnosing cancer in the bush: a mixed-methods study of symptom appraisal and help-seeking behaviour in people with cancer from rural Western Australia. Fam Pract (2013) 1.16
A distinctive colour associated with high iodine content in malignant pleural effusion from metastatic papillary thyroid cancer: a case report. J Med Case Rep (2013) 1.12
A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer (2004) 1.09
HIV-1 Tat recruits transcription elongation factors dispersed along a flexible AFF4 scaffold. Proc Natl Acad Sci U S A (2012) 1.08
Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. Pathology (2012) 1.07
Soluble mesothelin-related protein--a blood test for mesothelioma. Lung Cancer (2005) 1.06
A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer (2013) 1.00
Caring for someone with high-grade glioma: a time of rapid change for caregivers. Palliat Med (2010) 0.99
Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia. J Thorac Oncol (2009) 0.99
Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. Melanoma Res (2014) 0.97
Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting. Int J Colorectal Dis (2007) 0.96
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol (2009) 0.96
An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Invest New Drugs (2010) 0.94
A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer (2009) 0.94
A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs (2006) 0.94
Wnt antagonist, secreted frizzled-related protein 4 (sFRP4), increases chemotherapeutic response of glioma stem-like cells. Oncol Res (2013) 0.90
Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study. Asia Pac J Clin Oncol (2012) 0.89
Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol (2013) 0.89
One hundred years of research on the natural infection of freshwater snails by trematode larvae in Europe. Parasitol Res (2009) 0.88
Diagnosing cancer in the bush: a mixed methods study of GP and specialist diagnostic intervals in rural Western Australia. Fam Pract (2013) 0.88
Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. J Transl Med (2012) 0.88
Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: what makes it worthwhile? Lung Cancer (2011) 0.87
Concurrent adjuvant radiotherapy and interferon-alpha2b for resected high risk stage III melanoma -- a retrospective single centre study. Melanoma Res (2004) 0.87
BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid (2015) 0.86
A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer (2005) 0.84
Mastocytosis - an update. J Dtsch Dermatol Ges (2010) 0.84
Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncol (2007) 0.83
Bilateral thoracoscopy, mediastinoscopy and laparoscopy, in addition to CT, MRI and PET imaging, are essential to correctly stage and treat patients with mesothelioma prior to trimodality therapy. ANZ J Surg (2009) 0.83
Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer (2014) 0.82
Cytotoxic effects of the novel isoflavone, phenoxodiol, on prostate cancer cell lines. J Biosci (2012) 0.81
Small cell lung cancer presenting with paraneoplastic limbic encephalitis. Asia Pac J Clin Oncol (2011) 0.81
Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. Eur J Cancer (2008) 0.78
Radiotherapy in the management of high-grade gliomas diagnosed in Western Australia: a patterns of care study. J Med Imaging Radiat Oncol (2012) 0.78
FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor. Pathology (2015) 0.77
Bleeding Small Intestine Pyogenic Granuloma on 18F-FDG PET/CT. Clin Nucl Med (2015) 0.76
A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma. PLoS One (2010) 0.76
Treatment of superior sulcus non-small cell lung cancer. Asia Pac J Clin Oncol (2010) 0.75
Sentinel node biopsy for melanoma: The medical oncology perspective. Aust Fam Physician (2015) 0.75
Positive sentinel lymph node metastasis from a metastasis in Melanoma. Asia Pac J Clin Oncol (2014) 0.75
Testing for human papillomavirus in BRAF inhibitor-associated verrucous keratoses. J Cutan Pathol (2014) 0.75
Cutaneous Metastatic Melanoma Resembling a Halo Nevus, in the Setting of PD-1 Inhibition. Am J Dermatopathol (2016) 0.75